Here’s what you should know:
1. The company reported a 6 percent growth in year-over-year sales.
2. Boston Scientific posted net generally accepted accounting principle earnings of $146 million or $0.11 per share. In fiscal year 2016, Boston Scientific lost $207 million or -$0.15 per share.
3. Boston Scientific’s notable acquisitions included EndoChoice and Symetis SA during the second quarter.
4. Concerning rest-of-year outlooks, Boston Scientific expects net revenues between $8.89 billion to $8.99 billion, which is a slight increase from the beginning of year estimate of $8.8 billion to $8.9 billion.
More articles on gastroenterology:
Olympus to pay $6.6M in duodenoscope-related damages — 6 key takeaways
Boston Scientific continues to pour money into endoscopy — Why?
Staying relevant — Dr. Larry Kosinski on the future of GI in ASCs
